Vatelizumab

Vatelizumab is being developed as a treatment for relapsing MS, but the phase 2 trial was terminated early in 2016. We don't yet know the next steps for this treatment.

Find out more about vatelizumab

Vatelizumab is an antibody, just like those found in the immune system (where antibodies help fight infection). We don't fully know hoow vatelizumab works, but it is thought that it could alter the behaviour of immune cells, preventing them from entering the brain and spinal cord and therefore stopping them from attacking and damaging myelin.

Vatelizumab is an intravenous infusion.

EMPIRE trial

This phase 2 trial began in 2014 and aimed to test the safety and benefits of four doses of vatelizumab. It compared the treatment against a placebo in 112 people with relapsing MS.

The trial was terminated in 2016. We don't have any further details at this time.

Side effects were due to be measured in the EMPIRE trial, but we don't have details as the trial was terminated early.

Vatelizumab hasn’t yet been directly compared with other treatments for relapsing MS.

The phase 2 trial of vatelizumab was terminated early in 2016. We don't yet know the next steps for the treatment – we will keep you updated with the latest vatelizumab news.

You may also be interested in

Using MRI to investigate simvastatin in secondary progressive MS

Simvastatin is being tested as a potential treatment for secondary progressive MS. The drug showed promise in earlier clinical trials, reducing the rate of brain shrinkage by 43%, compared with placebo. This research is now being taken forward into a larger phase 3 trial, MS-STAT2, which began in 2017.

Can we reprogram myelin making cells to improve regeneration?

In MS, immune cells attack the protective myelin coating around our nerve cells. This project will see if researchers can partially re-program ageing oligodendrocytes progenitor cells (OPCs)